Clinical Trials Logo
  1. Home
  2. Alagille Syndrome
  3. NCT06193928

Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP) — LEAP  

Alagille Syndrome Clinical Trial

Official title:
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)

Clinical Trial Summary

The goal of this observational study is to evaluate the long-term safety and clinical outcomes of Livmarli prescribed to patients with Alagille Syndrome (ALGS).

Clinical Trial Description

Livmarli® is a novel, minimally absorbed, pharmacological treatment for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), a rare, genetic, autosomal dominant, complex multisystem disorder characterized by the presence of cholestasis (typically presenting as jaundice in the neonatal period) due to intrahepatic bile duct paucity. Livmarli inhibits the ileal bile acid transporter (IBAT) in the terminal ileum, leading to reduced levels of bile acids, thereby improving clinical manifestations and symptoms of cholestasis. Livmarli has been developed by Mirum Pharmaceuticals and approved by the US Food and Drug Administration (FDA) for the treatment of cholestatic pruritus in patients with ALGS who are 3 months of age and older. To be eligible for the study, participants must meet the following criteria: - A clinically and/or genetically confirmed ALGS diagnosis - Participant prescribed Livmarli ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06193928
Study type Observational [Patient Registry]
Source Mirum Pharmaceuticals, Inc.
Contact Clinical Trials Mirum
Phone +16506674085
Email Clinical Trials <clinicaltrials@mirumpharma.com>;
Status Recruiting
Phase
Start date September 21, 2023
Completion date September 20, 2028
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04729751 - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Phase 2
Active, not recruiting NCT05035030 - Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Phase 3
Completed NCT02160782 - Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) Phase 2
Completed NCT00007033 - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease N/A
Suspended NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02057692 - Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Phase 2
Active, not recruiting NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed NCT00001642 - Positional Cloning of the Gene(s) Responsible for Alagille Syndrome N/A
Recruiting NCT05488067 - Atorvastatin Therapy on Xanthoma in Alagille Syndrome Phase 4
Completed NCT04674761 - Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Phase 3
Completed NCT02117713 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome Phase 2
Completed NCT02131623 - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Phase 1
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Phase 1
Completed NCT02047318 - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) Phase 2
Completed NCT01903460 - Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome Phase 2
Completed NCT01515631 - Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
Enrolling by invitation NCT05846854 - Decreasing Hemorrhage Risk in Children With Alagille Syndrome N/A
Approved for marketing NCT04530994 - A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)